Halcion (Triazolam)

Halcion is a prescription oral tablet containing the benzodiazepine triazolam; the strength is not specified in the available data. It is marketed in the European Union and belongs to the hypnotic (sedative) therapeutic class. As a positive allosteric modulator of the GABA‑A receptor, Halcion enhances inhibitory neurotransmission to promote sleep. It is typically prescribed for short‑term management of difficulty falling asleep and is available only by prescription.

Halcion (triazolam) is indicated for short‑term treatment of insomnia when rapid onset of sleep is required.

- Short‑term relief of difficulty falling asleep, typically within 30 minutes. - Management of transient insomnia episodes that disrupt daily functioning. - Use in adults who require rapid sleep induction for shift‑work or jet‑lag. - Adjunct therapy when non‑pharmacologic measures, such as sleep hygiene, are insufficient. - Prescribed for a limited duration, usually not exceeding two weeks, to reduce tolerance.

Side effects of Halcion vary in frequency and severity; they are categorized as common or serious.

Common: - Drowsiness or fatigue, especially after the first dose. - Light‑headedness or dizziness that may affect coordination. - Impaired balance or motor skills, increasing fall risk. - Memory disturbances, such as anterograde amnesia for events after dosing. - Mood changes, including irritability or mild depression.

Serious: - Respiratory depression, particularly when combined with other depressants. - Severe allergic reactions, such as rash, itching, swelling, or anaphylaxis. - Paradoxical reactions, including agitation, aggression, or hallucinations.

When prescribing Halcion, clinicians consider several precautions to minimize risks and ensure safe use.

- Limit use to the shortest effective period to avoid dependence. - Assess for a history of substance abuse or addiction. - Avoid use in patients with severe respiratory disorders. - Use with caution in the elderly due to increased fall risk. - Contraindicated during pregnancy because of fetal risk (Category D). - Monitor for signs of withdrawal upon discontinuation.

Halcion may interact with other medications, affecting its sedative properties or metabolism.

Avoid: - Other central nervous system depressants (e.g., opioids, barbiturates, alcohol). - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin). - Drugs that prolong the QT interval.

Use with caution: - Antidepressants that lower seizure threshold. - Other benzodiazepines or sedative‑hypnotics.